This trial is testing a new drug to treat small cell lung cancer to see if it is safe and effective.
7 Primary · 11 Secondary · Reporting Duration: 24 months
7 Treatment Groups
1 of 7
1 of 7
1 of 7
1 of 7
Part A or Part B
1 of 7
1 of 7
1 of 7
382 Total Participants · 7 Treatment Groups
Primary Treatment: CRS Mitigation Strategies · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · All Participants · 12 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
- Owen, Dwight H., Michael J. Giffin, Julie M. Bailis, Marie-Anne Damiette Smit, David P. Carbone, and Kai He. 2019. “DLL3: An Emerging Target in Small Cell Lung Cancer”. Journal of Hematology & Oncology. Springer Science and Business Media LLC. doi:10.1186/s13045-019-0745-2.
- Owen DH, Giffin MJ, Bailis JM, Smit MD, Carbone DP, He K. DLL3: an emerging target in small cell lung cancer. J Hematol Oncol. 2019 Jun 18;12(1):61. doi: 10.1186/s13045-019-0745-2.
- Paz-Ares L, Champiat S, Lai WV, Izumi H, Govindan R, Boyer M, Hummel HD, Borghaei H, Johnson ML, Steeghs N, Blackhall F, Dowlati A, Reguart N, Yoshida T, He K, Gadgeel SM, Felip E, Zhang Y, Pati A, Minocha M, Mukherjee S, Goldrick A, Nagorsen D, Hashemi Sadraei N, Owonikoko TK. Tarlatamab, a First-In-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023 Jan 23:JCO2202823. doi: 10.1200/JCO.22.02823. Online ahead of print.
- 2017. "Study Evaluating Safety, Tolerability and PK of AMG 757 in Adults With Small Cell Lung Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03319940.
Frequently Asked Questions
Is participation in this medical experiment open at present?
"Affirmative. Clinicaltrials.gov conveys that this study is presently recruiting for 382 participants from 12 different medical sites, and was first announced on December 26th 2017 with its last update taking place on October 19th 2022." - Anonymous Online Contributor
How many healthcare centers are overseeing this clinical trial?
"This medical research is being conducted in 12 clinical settings, including the Ohio State University Wexner Medical Center, Washington University of Saint Louis and John Hopkins Sidney Kimmel Comprehensive Cancer Centre. The other locations are likewise specified on the study site." - Anonymous Online Contributor
What is the scope of recruitment for this investigation?
"Yes, as confirmed by the clinicaltrials.gov registry, this clinical research study is open to enrollment at 12 different sites and seeking 382 participants. The trial was initially posted on December 26th 2017 with its most recent update being October 19th 2022." - Anonymous Online Contributor
To what degree have CRS Mitigation Strategies been explored in prior research?
"Presently, 961 medical trials related to CRS Mitigation Strategies are in progress. Of those studies, 122 have progressed to Phase 3 of the trial process. While most of these trials are based out of Houston, TX, a total of 35 731 locations worldwide are involved with researching this potential treatment option." - Anonymous Online Contributor
Has the FDA approved CRS Mitigation Strategies for use in medical treatments?
"Since this is a Phase 1 trial, with limited data affirming its safety and efficacy, CRS Mitigation Strategies was given a rating of 1." - Anonymous Online Contributor
What sorts of medical conditions are CRS Mitigation Strategies usually employed to address?
"CRS Mitigation Strategies are routinely deployed to treat malignant neoplasms, in addition to unresectable melanoma, diseases with high microsatellite instability, and chemotherapy-resistant progression." - Anonymous Online Contributor